EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease
The CHMP has recommended approval for the SGLT2 inhibitor canagliflozin (Invokana) be extended to include diabetic kidney disease.International Approvals
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Canagliflozin | Diabetes | Endocrinology | Invokana | Kidney Transplant | Kidney Transplantation | SGLT2 Inhibitors | Transplant Surgery | Transplants | Urology & Nephrology
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024